CEMP Cempra, Inc.

3.35
+0.17  (5.51%)
Previous Close 3.17
Open 3.20
Price To book 0.80
Market Cap 175.48M
Shares 52,381,000
Volume 1,257,288
Short Ratio 2.76
Av. Daily Volume 2,267,620

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL announced December 29, 2016. Further trials required.
Solithera - intravenous
Community-acquired bacterial pneumonia (CABP)
CRL announced December 29, 2016. Further trials required.
Solithera - oral
Community-acquired bacterial pneumonia (CABP)
Phase 2 interim data released September 30, 2016. Enrollment completed. Data to be presented at upcoming conference. No timeline given.
Solithromycin
NASH
Phase 3 initiated August 2014. Enrollment completed December 2015 but decided to increase enrollment. Noted January 9, 2017 that extension enrollment has been slower than envisaged.
Solithromycin
Uncomplicated urogenital gonococcal infections
Phase 3 data due 1Q 2017.
Taksta - Fusidic acid
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 2 trial discontinued - noted January 9, 2017.
Solithromycin
COPD

Latest News

  1. Cempra to Report Fourth Quarter and Full Year 2016 Financial Results
  2. CORRECTING and REPLACING -- Cempra to Present at Upcoming Investor Conferences
  3. Cempra to Present at Upcoming Investor Conferences
  4. The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
  5. Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?
  6. Cempra (CEMP): An Off-the-Radar Potential Winner
  7. Latest Reports on Sarepta Therapeutics and Cempra as the NASDAQ Continues to Hit Record Highs
  8. CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  9. Cempra to Present at J.P. Morgan Healthcare Conference
  10. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Cempra, Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  11. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Cempra, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 3, 2017
  12. Is the Options Market Predicting a Spike in Cempra (CEMP) Stock?
  13. Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session
  14. EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Cempra, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
  15. Cempra: You Can Brag…
  16. GPM Reminds Investors of the January 3 Deadline in the Class Action Lawsuit Against Cempra, Inc.
  17. Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate
  18. Top Analyst Upgrades and Downgrades: Tesla Motors, Kate Spade, Xilinx, Yandex, Cempra and More
  19. Blog Coverage Cempra's Stock Price Dropped Following US FDA Rejection of Its Pneumonia Drug
  20. Cempra shares crater on concerns about delay in getting pneumonia drug approved